Aclaris Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Aclaris TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 4.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 13% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 2.5% pro Jahr wachsen.

Wichtige Informationen

-4.4%

Wachstumsrate der Gewinne

2.5%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.4%
Wachstumsrate der Einnahmen	13.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0H8T - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10	-56	-57	-46	5
12/31/2025	12	-43	-43	-30	8
12/31/2024	16	-42	-17	15	7
9/30/2024	27	-37	-18	-18	N/A
6/30/2024	32	-59	-65	-64	N/A
3/31/2024	31	-77	-74	-73	N/A
12/31/2023	31	-88	-80	-78	N/A
9/30/2023	21	-115	-92	-91	N/A
6/30/2023	31	-105	-75	-74	N/A
3/31/2023	31	-96	-74	-73	N/A
12/31/2022	30	-87	-68	-68	N/A
9/30/2022	24	-82	-66	-66	N/A
6/30/2022	6	-83	-69	-68	N/A
3/31/2022	6	-81	-61	-61	N/A
12/31/2021	7	-91	-52	-52	N/A
9/30/2021	7	-82	-44	-44	N/A
6/30/2021	7	-71	-46	-45	N/A
3/31/2021	7	-65	-44	-44	N/A
12/31/2020	6	-51	-39	-39	N/A
9/30/2020	6	-57	-51	-50	N/A
6/30/2020	6	-69	-63	-61	N/A
3/31/2020	4	-102	-73	-72	N/A
12/31/2019	4	-114	-98	-96	N/A
9/30/2019	5	-118	-105	-103	N/A
6/30/2019	5	-115	-111	-110	N/A
3/31/2019	6	-79	-112	-110	N/A
12/31/2018	6	-82	-102	-101	N/A
9/30/2018	5	-81	-94	-92	N/A
6/30/2018	5	-79	N/A	-76	N/A
3/31/2018	3	-86	N/A	-64	N/A
12/31/2017	2	-50	N/A	-55	N/A
9/30/2017	1	-57	N/A	-45	N/A
6/30/2017	N/A	-50	N/A	-41	N/A
3/31/2017	N/A	-48	N/A	-40	N/A
12/31/2016	N/A	-48	N/A	-35	N/A
9/30/2016	N/A	-42	N/A	-31	N/A
6/30/2016	N/A	-42	N/A	-31	N/A
3/31/2016	N/A	-33	N/A	-24	N/A
12/31/2015	N/A	-23	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-19	N/A
6/30/2015	N/A	-13	N/A	-10	N/A
3/31/2015	N/A	-12	N/A	-9	N/A
12/31/2014	N/A	-11	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0H8T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0H8T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0H8T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0H8TDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0H8TDie Einnahmen des Unternehmens (13% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0H8T in 3 Jahren voraussichtlich hoch sein wird

Aclaris Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.42 loss in 2Q 2023)

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Growth Index

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Aclaris Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings released: US$1.27 loss per share (vs US$1.33 loss in FY 2022)

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.30 loss in 3Q 2022)

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Chief Financial Officer recently bought US$75k worth of stock

Chief Business Officer recently bought US$100k worth of stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 1Q 2022)

Co-Founder & Chairman recently sold US$510k worth of stock

Full year 2022 earnings released: US$1.33 loss per share (vs US$1.60 loss in FY 2021)

Chief Business Officer recently sold US$59k worth of stock

Aclaris Therapeutics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2021)

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Executive Changes

Aclaris Therapeutics, Inc. Appoints Gail Cawkwell as Chief Medical Officer

Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development

First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.57 loss in 1Q 2021)

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold US$896k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Aclaris Therapeutics, Inc. Names James Loerop as Chief Business Officer, Effective January 31, 2022

Aclaris Therapeutics Provides R&D Update

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.25 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2020)

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Value Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from Phase 2A Trial of ATI-1777

Co-Founder recently sold US$258k worth of stock

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.37 loss in 1Q 2020)

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Full year 2020 earnings released: US$1.20 loss per share (vs US$2.75 loss in FY 2019)

Revenue beats expectations

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $95.964995 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from 12-Week Phase 2A Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken